Growth hormone co-treatment on controlled ovarian stimulation in normal ovarian response women can improve embryo quality
Authors:
- 23 March 2019
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 35 (9) , 787-791
Abstract
To investigate the clinical efficacy of growth hormone (GH) in normal response patients with poor embryo quality in previous in vitro fertilization cycles. A total of 1562 infertile women were enrolled in this matched case–control study: 781 women were treated with GH (study group), whereas 781 matched patients were treated without GH (control group). GH was administered by a daily subcutaneous injection of 2 or 4 IU started from either D2 of the previous cycle (6 weeks GH pretreatment) or the initial day of controlled ovarian stimulation (2 weeks GH pretreatment) until hCG trigger. The study group was further divided into four subgroups: 2 IU-6 weeks GH pretreatment, 4 IU-6 weeks GH pretreatment, 2 IU-2 weeks GH pretreatment, and 2 IU-4 weeks GH pretreatment. Patients receiving GH showed significantly lower Gn dosage. The total number of oocytes retrieved, embryos formed, endometrial thickness on hCG day were significantly higher with GH. 2PN rate and high-quality embryo rate were lower in the GH group. However, GH increased clinical pregnancy rate with significant difference. 4 IU-6 weeks GH pretreatment showed lowest duration of Gn and highest clinical pregnancy rate compared with other three groups. Number of transferred embryos was confounding factor both in univariate and multivariate analysis. Our study showed that co-treatment with GH in patients with normal ovarian response could increase pregnancy rate.Keywords
This publication has 14 references indexed in Scilit:
- Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled studyArchives of Gynecology and Obstetrics, 2017
- The value of growth hormone supplements in ART for poor ovarian respondersFertility and Sterility, 2011
- Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer riskGynecologic Oncology, 2011
- Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysisHuman Reproduction Update, 2009
- How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysisFertility and Sterility, 2009
- The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literatureFertility and Sterility, 2009
- Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormoneHuman Reproduction, 2005
- Follicular fluid markers of oocyte developmental potentialHuman Reproduction, 2002
- Integrins as markers of uterine receptivity in women with primary unexplained infertilityFertility and Sterility, 1995
- Evidence from the use of monoclonal antibody probes for structural heterogeneity of the growth hormone receptorBiochemical Journal, 1985